What's Happening?
Amylyx Pharmaceuticals has announced the publication of results from its Phase 2 open-label HELIOS trial in The Journal of Clinical Investigation. The trial evaluated AMX0035, a combination of sodium phenylbutyrate
and taurursodiol, in adults with Wolfram syndrome. The study showed improvements in pancreatic beta cell function and glycemic control over 48 weeks, with stabilization in visual acuity. The trial's findings suggest AMX0035's potential to alter the progression of Wolfram syndrome, a rare genetic disorder characterized by diabetes and neurodegeneration. The drug was generally well-tolerated, with no serious adverse events reported.
Why It's Important?
The publication of these results is significant as Wolfram syndrome currently lacks FDA-approved treatments. The trial's positive outcomes offer hope for a disease-modifying therapy that could improve the quality of life for patients. The findings also support the continued development of AMX0035, which has received Orphan Drug Designation from the FDA and European Commission. This development could pave the way for future treatments targeting neurodegenerative diseases, potentially benefiting a broader patient population.
What's Next?
Amylyx Pharmaceuticals plans to continue working with the FDA on a Phase 3 trial for AMX0035 in Wolfram syndrome. The company also intends to present additional long-term data from the HELIOS trial at upcoming scientific meetings. These steps are crucial for advancing the drug towards potential regulatory approval and broader clinical use.
